PharmaCyte Biotech Inc (PMCB)

[Edward]

He stated what they are:

1) Completion of the second run

2)Release testing

A few other key events will play themselves out in the weeks to come—all leading to the submission of the IND.  The first of which has already begun.  PharmaCyte stated this week that the second of two staggered and back-to-back manufacturing runs is already underway, and that the cells from the company’s Master Cell Bank (MCB) are growing well in this second run and will be encapsulated within the next week or two.

The most important event left to complete outside of the final manufacturing run is “release testing” of the clinical trial product.  PharmaCyte said that a representative sample of frozen syringes from the first successful manufacturing run, which are filled with 300 Cell-in-a-Box® capsules each, are in the process of being shipped to external testing labs for the release testing that is required by the FDA

The data that those tests will produce are all that remains for the company to complete the IND and then submit it to the FDA.